Fidelia Elvira Da Costa Rao

Fidelia Elvira Da Costa Rao

Auto-generated profile, based on publicly available information

Fidelia Elvira Da Costa Rao

Department of Medicine, University of California, San Diego, and San Diego Veterans Affairs Healthcare System, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2009 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
MFM. M. Fung
M. M. Fung
YCYu Chen
Yu Chen
MLM. S. Lipkowitz
M. S. Lipkowitz
RSR. M. Salem
R. M. Salem
VISHAL BHATNAGARVISHAL BHATNAGAR
VISHAL BHATNAGAR
FCfor the AASK Co-Investigators
for the AASK Co-Investigators
End-stage renal disease (ESRD) due to hypertension is common and displays familial aggregation in African Americans, suggesting genetic risk factors, including adrenergic activity alterations which are noted in both hypertension and ESRD. We analysed 554 hypertensive nephrosclerosis participants (without clinically significant proteinuria) from the longitudinal National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) African American Study of Kidney Disease and Hypertension (AASK) cohort to determine whether decline in glomerular filtration rate (GFR) over approximately 3.8 years was predicted by common genetic variation within the adrenergic beta-1 (ADRB1) receptor at non-synonymous positions Ser49Gly and Arg389Gly. The polymorphism at Ser49Gly (though not Arg389Gly, in only partial linkage disequilibrium at r(2) = 0.18) predicted the chronic rate of GFR decline, with minimal decline in Gly(49)/Gly(49) (minor allele) homozygotes compared to Ser(49) carriers; concordant results were observed for haplotypes and diploid haplotype pairs at the locus. An independent replication study in 1244 subjects from the San Diego Veterans Affairs Hypertension Cohort confirmed that Gly(49)/Gly(49) homozygotes displayed the least rapid decline of eGFR over approximately 3.6 years. We conclude that GFR decline rate in hypertensive renal disease is controlled in part by genetic variation within the adrenergic pathway, particularly at ADRB1. The results suggest novel strategies to approach the role of the adrenergic system in the risk and treatment of progressive renal disease.

1 June 2013 in EP Europace
Verified
Journal Article
Open access
PDF file
FRF. Rao
F. Rao
CDChu-xia Deng
Chu-xia Deng
YXY. Xue
Y. Xue
QZQ. Zhang
Q. Zhang
HDHongwen Deng
Hongwen Deng
RHR. Hatala
R. Hatala
Introduction: Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Recent findings have demonstrated a mechanistic link between inflammatory and the development of AF. Macrophage migration inhibitory factor (MIF), a pleiotropic cytokine, controls the inflammatory ‘set point’ by regulating the release of other pro-inflammatory cytokines. Recent studies have revealed that Connexin 43 (Cx 43) not only is involved in the electrical conductivity between the cells, but also forms a complex with PKP2 and Na+ channel to affect the sodium current. The purpose of this study is to observe the role of MIF in the expression of Cx43, and the role of Cx43 in the regulation of calcium channel current in atrial myocytes.

5 June 2024 in Romanian Medical Journal
Verified
Journal Article
Closed access
FRFidelia Elvira Da Costa Rao
Fidelia Elvira Da Costa Rao
FSFemi Syahriani
Femi Syahriani
HRHaerani Rasyid
Haerani Rasyid
SBSyakib Bakri
Syakib Bakri
HIHarun Iskandar
Harun Iskandar
AZAndi A. Zainuddin
Andi A. Zainuddin